Evidence from in vitro studies, animal models, and molecular docking analyses suggests that trigonelline holds therapeutic potential for neurodegenerative disorders including AD, PD, and depression through mechanisms involving oxidative stress mitigation, neuroinflammatory suppression, and AChE inhibition (Figure 2) (50–52). This evidence concerns the gene ACHE and Parkinson disease.